ACN Newswire

Tue Jan 19

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

Written by ACN Newswire

HONG KONG, Jan 18, 2021 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy...

ACN Newswire

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

Decoding the music masterpieces: Rossini's opera, Otello

China's disinformation threat is real. We need better defences against state-based cyber campaigns

Protecting the places we love: here are 7 ways our nature laws must be fixed

Portrait of Hemi Pomara as a young man: how we uncovered the oldest surviving photograph of a Māori

Can Ne Zha, the Chinese superhero with $1b at the box office, teach us how to raise good kids?

Cuba and U.S. Skirt Obstacles to Normalisation of Ties

GOD save us: greenspace-oriented development could make higher density attractive

Morrison tells Liberal organisation to act on bullying after second woman flags she'll quit

When it comes to violent brawls, does Victoria need more 'force'?

The Meg! When the (giant prehistoric) shark bites, the science bites back

To our 20,000 donors, thank you – your support has secured our future for another year